Viracta Therapeutics, Inc. (VIRX)
NASDAQ: VIRX · Real-Time Price · USD
0.161
+0.009 (5.79%)
At close: Nov 22, 2024, 4:00 PM
0.154
-0.007 (-4.17%)
After-hours: Nov 22, 2024, 6:37 PM EST
Viracta Therapeutics Stock Forecast
VIRX's stock price has decreased by -70.47% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for VIRX stock have an average target of 5.00, with a low estimate of 2.00 and a high estimate of 11. The average target predicts an increase of 3,011.39% from the current stock price of 0.16.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VIRX stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $4 → $2 | Buy | Maintains | $4 → $2 | +1,144.56% | Nov 14, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $5 → $3 | Buy → Hold | Downgrades | $5 → $3 | +1,766.83% | Aug 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +2,389.11% | Aug 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $13 → $11 | Buy | Maintains | $13 → $11 | +6,745.05% | May 23, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $13 | Buy | Maintains | $13 | +7,989.61% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
3.57M
EPS This Year
-0.89
from -1.32
EPS Next Year
-0.63
from -0.89
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 7.4M | 40.7M | ||
| Avg | n/a | 3.6M | 19.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 1,038.8% | ||
| Avg | - | - | 453.1% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.72 | -0.37 | -0.35 | ||
| Avg | -0.89 | -0.63 | -0.37 | ||
| Low | -1.03 | -0.86 | -0.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.